800-872-2273

Ensayos clínicos y estudios

Su participación es importante. ¡Ayúdenos a encontrar la cura!

Contáctenos al (800) USC-CARE (800-872-2273)

5 Results for

Study Title Principal Investigator
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Completed | Parkinson's Disease | Multisite
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
This is a multi-center, multi-national, randomized, parallel-group, placebo-controlled, double-blind study with a 17 week (maximum) treatment period consisting of an initial, open-label dose titration (up to 2 weeks), followed by a washout period (up to 3 weeks), followed by a 12 week treatment period on a stable dose.
Recruiting | Parkinson's Disease | Multisite
Horacio Kaufmann
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
No longer available | Parkinson's Disease | Multisite
Harald Murck
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy
Active, not recruiting | Parkinson's Disease | Multisite
Ronald Pfeiffer
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Completed | Parkinson's Disease | Multisite
Mark Lew
View Research Profile
Presentado por SC CTSI